| pubmed-article:11350862 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:11350862 | lifeskim:mentions | umls-concept:C0013227 | lld:lifeskim |
| pubmed-article:11350862 | lifeskim:mentions | umls-concept:C1280500 | lld:lifeskim |
| pubmed-article:11350862 | lifeskim:mentions | umls-concept:C1880177 | lld:lifeskim |
| pubmed-article:11350862 | lifeskim:mentions | umls-concept:C0441712 | lld:lifeskim |
| pubmed-article:11350862 | pubmed:issue | 2 | lld:pubmed |
| pubmed-article:11350862 | pubmed:dateCreated | 2001-5-14 | lld:pubmed |
| pubmed-article:11350862 | pubmed:abstractText | The hypotensive effect of imidazoline-like drugs, such as clonidine, was first attributed to the exclusive stimulation of central alpha2-adrenoceptors (alpha2ARs). However, a body of evidence suggests that non-adrenergic mechanisms may also account for this hypotension. This work aims (i) to check whether imidazoline-like drugs with no alpha2-adrenergic agonist activity may alter blood pressure (BP) and (ii) to seek a possible interaction between such a drug and an alpha2ARs agonist alpha-methylnoradrenaline (alpha-MNA). We selected S23515 and S23757, two imidazoline-like drugs with negligible affinities and activities at alpha2ARs but with high affinities for non-adrenergic imidazoline binding sites (IBS). S23515 decreased BP dose-dependently (-27+/-5% maximal effect) when administered intracisternally (i.c.) to anaesthetized rabbits. The hypotension induced by S23515 (100 microg kg(-1) i.c.) was prevented by S23757 (1 mg kg(-1) i.c.) and efaroxan (10 microg kg(-1) i.c.), while these compounds, devoid of haemodynamic action by themselves, did not alter the hypotensive effect of alpha-MNA (3 and 30 microg kg(-1) i.c.). Moreover, the alpha2ARs antagonist rauwolscine (3 microg kg(-1) i.c.) did not prevent the effect of S23515. Finally, whilst 3 microg kg(-1) of S23515 or 0.5 microg kg(-1) of alpha-MNA had weak hypotensive effects, the sequential i.c. administration of these two drugs induced a marked hypotension (-23+/-2%). These results indicate that an imidazoline-like drug with no alpha2-adrenergic properties lowers BP and interacts synergistically with an alpha(ARs agonist. | lld:pubmed |
| pubmed-article:11350862 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11350862 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11350862 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11350862 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11350862 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11350862 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11350862 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11350862 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11350862 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11350862 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11350862 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11350862 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11350862 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11350862 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11350862 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11350862 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11350862 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11350862 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11350862 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11350862 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11350862 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11350862 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11350862 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11350862 | pubmed:language | eng | lld:pubmed |
| pubmed-article:11350862 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11350862 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:11350862 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11350862 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11350862 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11350862 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11350862 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11350862 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11350862 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:11350862 | pubmed:month | May | lld:pubmed |
| pubmed-article:11350862 | pubmed:issn | 0007-1188 | lld:pubmed |
| pubmed-article:11350862 | pubmed:author | pubmed-author:FeldmanJJ | lld:pubmed |
| pubmed-article:11350862 | pubmed:author | pubmed-author:BousquetPP | lld:pubmed |
| pubmed-article:11350862 | pubmed:author | pubmed-author:BoutinJJ | lld:pubmed |
| pubmed-article:11350862 | pubmed:author | pubmed-author:PayardMM | lld:pubmed |
| pubmed-article:11350862 | pubmed:author | pubmed-author:PfeifferBB | lld:pubmed |
| pubmed-article:11350862 | pubmed:author | pubmed-author:RenardPP | lld:pubmed |
| pubmed-article:11350862 | pubmed:author | pubmed-author:VanhouttePP | lld:pubmed |
| pubmed-article:11350862 | pubmed:author | pubmed-author:ScalbertEE | lld:pubmed |
| pubmed-article:11350862 | pubmed:author | pubmed-author:DontenwillMM | lld:pubmed |
| pubmed-article:11350862 | pubmed:author | pubmed-author:GrenetCC | lld:pubmed |
| pubmed-article:11350862 | pubmed:author | pubmed-author:JarryCC | lld:pubmed |
| pubmed-article:11350862 | pubmed:author | pubmed-author:SchanoPP | lld:pubmed |
| pubmed-article:11350862 | pubmed:author | pubmed-author:BrubanVV | lld:pubmed |
| pubmed-article:11350862 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:11350862 | pubmed:volume | 133 | lld:pubmed |
| pubmed-article:11350862 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:11350862 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:11350862 | pubmed:pagination | 261-6 | lld:pubmed |
| pubmed-article:11350862 | pubmed:dateRevised | 2009-11-18 | lld:pubmed |
| pubmed-article:11350862 | pubmed:meshHeading | pubmed-meshheading:11350862... | lld:pubmed |
| pubmed-article:11350862 | pubmed:meshHeading | pubmed-meshheading:11350862... | lld:pubmed |
| pubmed-article:11350862 | pubmed:meshHeading | pubmed-meshheading:11350862... | lld:pubmed |
| pubmed-article:11350862 | pubmed:meshHeading | pubmed-meshheading:11350862... | lld:pubmed |
| pubmed-article:11350862 | pubmed:meshHeading | pubmed-meshheading:11350862... | lld:pubmed |
| pubmed-article:11350862 | pubmed:meshHeading | pubmed-meshheading:11350862... | lld:pubmed |
| pubmed-article:11350862 | pubmed:meshHeading | pubmed-meshheading:11350862... | lld:pubmed |
| pubmed-article:11350862 | pubmed:meshHeading | pubmed-meshheading:11350862... | lld:pubmed |
| pubmed-article:11350862 | pubmed:meshHeading | pubmed-meshheading:11350862... | lld:pubmed |
| pubmed-article:11350862 | pubmed:meshHeading | pubmed-meshheading:11350862... | lld:pubmed |
| pubmed-article:11350862 | pubmed:meshHeading | pubmed-meshheading:11350862... | lld:pubmed |
| pubmed-article:11350862 | pubmed:meshHeading | pubmed-meshheading:11350862... | lld:pubmed |
| pubmed-article:11350862 | pubmed:meshHeading | pubmed-meshheading:11350862... | lld:pubmed |
| pubmed-article:11350862 | pubmed:meshHeading | pubmed-meshheading:11350862... | lld:pubmed |
| pubmed-article:11350862 | pubmed:meshHeading | pubmed-meshheading:11350862... | lld:pubmed |
| pubmed-article:11350862 | pubmed:meshHeading | pubmed-meshheading:11350862... | lld:pubmed |
| pubmed-article:11350862 | pubmed:meshHeading | pubmed-meshheading:11350862... | lld:pubmed |
| pubmed-article:11350862 | pubmed:year | 2001 | lld:pubmed |
| pubmed-article:11350862 | pubmed:articleTitle | Respective contributions of alpha-adrenergic and non-adrenergic mechanisms in the hypotensive effect of imidazoline-like drugs. | lld:pubmed |
| pubmed-article:11350862 | pubmed:affiliation | Laboratoire de Neurobiologie et Pharmacologie Cardiovasculaire, Faculté de Médecine, Université Louis Pasteur, 11 rue Humann, 67000 Strasbourg, France. | lld:pubmed |
| pubmed-article:11350862 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:11350862 | pubmed:publicationType | In Vitro | lld:pubmed |
| pubmed-article:11350862 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:11350862 | lld:pubmed |
